Literature DB >> 25069443

Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism.

Damiano M Cereghetti, Peter P Lee1.   

Abstract

Tumor-derived vesicles (TDV) have been recently implicated in immunosuppression by transporting specific proteins, including Fas ligand (FasL) and TRAIL, to immune cells. We hypothesized that TDVs carrying miRNAs with immunological function could interfere with the translational machinery of immune cells and lead to TDV-mediated immunosuppression in cancer. We show that TDVs from human tumor cells indeed contain multiple miRNA species with known roles in lymphocyte development and function: hsa-miR-146a, miR-29a, and miR-21. Quantification by RT-PCR shows that the amount of miR-21 within TDVs isolated from the breast cancer cell line HCC1806 is at physiologically relevant levels. Additionally, we show that these miRNAs carried by TDVs copurify with argonaute proteins. This observation corroborates the idea that the machinery of microvesicle secretion and that of RNA interference are interconnected.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25069443     DOI: 10.2174/22115366113029990012

Source DB:  PubMed          Journal:  Microrna


  14 in total

Review 1.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 2.  An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.

Authors:  Wenhao Weng; Junlan Feng; Huanlong Qin; Yanlei Ma; Ajay Goel
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

Review 3.  Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.

Authors:  Marzia Pucci; Pablo Reclusa Asiáin; Elena Duréndez Sáez; Eloisa Jantus-Lewintre; Mahafarin Malarani; Shahanavaj Khan; Simona Fontana; Aung Naing; Francesco Passiglia; Luis E Raez; Christian Rolfo; Simona Taverna
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 4.  Immunomodulatory role of microRNAs transferred by extracellular vesicles.

Authors:  Lola Fernández-Messina; Cristina Gutiérrez-Vázquez; Eva Rivas-García; Francisco Sánchez-Madrid; Hortensia de la Fuente
Journal:  Biol Cell       Date:  2015-02-12       Impact factor: 4.458

5.  Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis.

Authors:  Taixue An; Sihua Qin; Yong Xu; Yueting Tang; Yiyao Huang; Bo Situ; Jameel M Inal; Lei Zheng
Journal:  J Extracell Vesicles       Date:  2015-06-19

Review 6.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

7.  Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation.

Authors:  K Sugimachi; T Matsumura; H Hirata; R Uchi; M Ueda; H Ueo; Y Shinden; T Iguchi; H Eguchi; K Shirabe; T Ochiya; Y Maehara; K Mimori
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

Review 8.  The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?

Authors:  Katherine E Kunigelis; Michael W Graner
Journal:  Vaccines (Basel)       Date:  2015-12-17

9.  Heterogeneous Nuclear Ribonucleoprotein A1 Loads Batched Tumor-Promoting MicroRNAs Into Small Extracellular Vesicles With the Assist of Caveolin-1 in A549 Cells.

Authors:  Yangyang Li; Jian Zhang; Sha Li; Chongye Guo; Qian Li; Xin Zhang; Meng Li; Shuangli Mi
Journal:  Front Cell Dev Biol       Date:  2021-06-17

10.  Identification of Recurrence-Related microRNAs from Bone Marrow in Hepatocellular Carcinoma Patients.

Authors:  Keishi Sugimachi; Shotaro Sakimura; Akira Tomokuni; Ryutaro Uchi; Hidenari Hirata; Hisateru Komatsu; Yoshiaki Shinden; Tomohiro Iguchi; Hidetoshi Eguchi; Takaaki Masuda; Kazutoyo Morita; Ken Shirabe; Hidetoshi Eguchi; Yoshihiko Maehara; Masaki Mori; Koshi Mimori
Journal:  J Clin Med       Date:  2015-08-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.